How to buy Affimed N-V stock

Affimed N.V is a biotechnology business based in the US. Affimed N-V shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed N-V employs 137 staff and has a trailing 12-month revenue of around 0.00.

Affimed N-V share price

Use our graph to track the performance of AFMD stocks over time.

Affimed N-V shares at a glance

• Key figures

Information last updated 2021-03-29.

52-week range	$1.50 - $8.60
50-day moving average	$6.55
200-day moving average	$5.31
Wall St. target price	$12.41
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.72

Buy Affimed N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Affimed N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Affimed N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Affimed N-V financials

Revenue TTM	$26.9 million
Gross profit TTM	$21.4 million
Return on assets TTM	-22.94%
Return on equity TTM	-114.04%
Profit margin	-175.03%
Book value	$0.64
Market capitalisation	$891.9 million

TTM: trailing 12 months

Shorting Affimed N-V shares

There are currently 6.9 million Affimed N-V shares held short by investors – that's known as Affimed N-V's "short interest". This figure is 7.1% down from 7.5 million last month.

There are a few different ways that this level of interest in shorting Affimed N-V shares can be evaluated.

Affimed N-V's "short interest ratio" (SIR)

Affimed N-V's "short interest ratio" (SIR) is the quantity of Affimed N-V shares currently shorted divided by the average quantity of Affimed N-V shares traded daily (recently around 2.0 million). Affimed N-V's SIR currently stands at 3.4. In other words for every 100,000 Affimed N-V shares traded daily on the market, roughly 3400 shares are currently held short.

However Affimed N-V's short interest can also be evaluated against the total number of Affimed N-V shares, or, against the total number of tradable Affimed N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affimed N-V's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Affimed N-V shares in existence, roughly 60 shares are currently held short) or 0.0624% of the tradable shares (for every 100,000 tradable Affimed N-V shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affimed N-V.

Find out more about how you can short Affimed N-V stock.

Affimed N-V share dividends

We're not expecting Affimed N-V to pay a dividend over the next 12 months.

Affimed N-V share price volatility

Over the last 12 months, Affimed N-V's shares have ranged in value from as little as $1.5 up to $8.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed N-V's is 2.545. This would suggest that Affimed N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Affimed N-V overview

Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc.

Frequently asked questions

• What percentage of Affimed N-V is owned by insiders or institutions?

  Currently 6.408% of Affimed N-V shares are held by insiders and 55.274% by institutions.

• How many people work for Affimed N-V?

  Latest data suggests 137 work at Affimed N-V.

• When does the fiscal year end for Affimed N-V?

  Affimed N-V's fiscal year ends in December.

• Where is Affimed N-V based?

  Affimed N-V's address is: Technologiepark, Heidelberg, Germany, 69120

• What is Affimed N-V's ISIN number?

  Affimed N-V's international securities identification number is: NL0010872420

• What is Affimed N-V's CUSIP number?

  Affimed N-V's Committee on Uniform Securities Identification Procedures number is: N01045108